We retrospectively analyzed data on T-and B-cell reconstitution and infectious complications in 58 children undergoing ABMT, in order to evaluate post-transplant supportive care measures used during the study period. Normalization of T-cell number and lymphocyte proliferative responses to phytohemagglutinin (PHA) and alloantigen (MLC) occurred in two-thirds of children by 6 months post transplant. Normal IgM levels developed in 75% of children by 6 months post transplant. A total of 34 children (59%) developed 39 episodes of infection between neutrophil engraftment and 1 year post transplant. The most common infections included bacteremia, varicellazoster virus infection and pneumonia, which represented 46, 23 and 9% of infections, respectively. All patients with bacteremia had a central venous catheter in place at the time of infection. Most infections (77%) developed by 6 months post transplant. In this small patient cohort, time to normalization of tests of T-and B-cell function was not significantly different between patients with and without infection. Earlier removal of an indwelling central venous catheter may decrease the risk of bacteremia post transplant. Post-transplant supportive care measures may be discontinued at 6 months post ABMT in most children, as the risk of infection decreases after that time.
transplant
Many studies of immune reconstitution after autologous BMT in adults have been reported. [1] [2] [3] [4] In children, only limited data on immune reconstitution after ABMT are available. 5, 6 Recently, with the use of CD34+ selection in adult autologous transplant recipients, there has been increased interest in studying post transplant infections. 7 To date, studies examining both immune reconstitution and the risk of infection in adult or pediatric autologous transplant recipients are scarce. 8 Supportive care measures, geared to prevent infections during the time of posttransplant immunosuppression, vary significantly among institutions. In October of 2000, The Center for Disease Control and Prevention (CDC) published guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Due to lack of data, many of the CDC recommendations are still based on expert opinions rather than on clinical studies. 9 The goal of this retrospective study was to evaluate if post transplant supportive care measures used at our institution prior to the adoption of CDC recommendations affected the risk of infection. Our supportive care measures included use of modified protective isolation, prophylactic use of acyclovir, oral nystatin or clotrimazole, and trimethoprim/sulfamethoxazole until normalization of in vitro T-cell function tests, and use of intravenous immunglobulin until normalization of IgM and isohemagglutinin titers. We present our data on immune reconstitution, infectious complications and their relation to the use of post-transplant supportive care measures. Our results provide additional information for evidence-based post transplant supportive care guidelines in children.
Patients and methods
All patients undergoing autologous transplant at the University of California, San Francisco Pediatric Bone Marrow Transplant Unit between 1992 and 2000 were included in this retrospective analysis (N ¼ 98). Patients who relapsed or died within a year of transplant were excluded (N ¼ 40), leaving 58 eligible patients. Patients were monitored for immune reconstitution and infections from the time of neutrophil engraftment until 1 year post transplant. The characteristics of patients, including diagnoses, age, previous therapy, conditioning regimen, stem cell source and previous exposure to herpes viruses, are presented in Table 1 . A total of 50% of patients had neuroblastoma and have undergone an intensive conditioning regimen consisting of carboplatin, etoposide and melphalan with or without TBI and have received purged stem cell product. The method for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads has been previously described. 10 All patients underwent intensive chemotherapy prior to transplant, and the majority of patients (75%) underwent pretransplant surgery and irradiation.
Tests of immune reconstitution
T-and B-cell immunity was routinely measured at 3-month intervals in all patients undergoing transplantation until full recovery was achieved. B-cell immunity was measured by determining IgM levels (normal X40 mg/dl), and anti-A and anti-B IgM isohemagglutinin titers (normal X1:8). Neutrophil engraftment was defined as the first of three consecutive days on which the absolute neutrophil count exceeded 0.5 Â 10 9 /l after transplantation. T-and B-cell lymphocyte subsets were quantified by flow cytometric analysis using fluorochrome-conjugated monoclonal antibodies to human cell-surface antigens (CD3, CD4, CD8, CD19, CD56) and a FACScan analyzer (Becton Dickinson, Mountain View, CA, USA). In vitro T-cell function was measured by lymphocyte proliferative responses to phyto- H-thymidine, as previously described.
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Postdischarge supportive care measures Supportive care measures during the hospital stay were previously described. 12 Once discharged from the hospital, children continued with modified protective isolation, consisting of avoiding contacts with sick people and following food safety guidelines, similar to those described in the CDC guidelines. 9 Trimethoprim/sulfamethoxazole was used for Pneumocystis carinii prophylaxis, nonabsorbable antifungal agents, such as nystatin or clotrimazole, were used for the prophylaxis of oral candidasis, oral acyclovir 800 mg/m 2 / day in two to three divided doses was used for prophylaxis against herpes viruses, and intravenous immunoglobulin (IVIG) (200-400 mg/kg every 4 weeks) was given to all patients. All prophylactic measures, other than IVIG infusion, were discontinued once in vitro tests of T-cell immunity normalized (defined as absolute lymphocyte count (ALC) 41000/ml, and normal PHA (432000 cpm) and/or MLC (418000 cpm)). IVIG infusion was discontinued once B-cell recovery was achieved (IgM 440 mg/dl and isohemagglutinin titer X1:8). No specific guidelines about timing of the removal of the child's central venous catheter were followed; the decision about its removal was left to the patient and primary oncologist.
Data collection and analysis
After obtaining IRB approval, data were collected by searching the UCSF pediatric BMT database, computerized hospital medical records and individual charts. Data related to the patient's diagnosis and previous treatments, conditioning regimen, source of stem cells, immune reconstitution and type and time of infection were collected. Data on infections was gathered retrospectively through chart review. We included episodes of infections that were documented by a positive culture, radiologic exam or a physical exam. Episodes of fever, without documented pathogen or site of infection, were not counted. We used descriptive statistics, the two-tailed Fisher's exact test and w 2 when testing associations of independent variables, and the two-tailed t-test for the comparison of means. Data were analyzed using SPSS for Windows (SPSS, Chicago, IL, USA).
Results

Immune reconstitution
The median time to neutrophil recovery was 16.9 days (range 6-60). Neutrophil recovery was significantly longer in patients receiving purged stem cell products than in patients receiving unmodified stem cells (19.2 vs 13.7 days, P ¼ 0.03). However, there was no difference in time to recovery of T-and B-cell function in these two groups of patients. Also, there was no statistically significant difference in time to normalization of T-and B-cell function tests between patients receiving bone marrow and those receiving peripheral blood progenitor cells (data not presented). By 6 months post transplant, 85.7% of all children had an ALC 41000/ml, 59.5% had a CD4 count 4200/ml, 46.2% had a normal CD4/CD8 ratio, 64.2% had developed normal PHA response, 67.6% had developed normal MLC response, 75.5% had an IgM level 440 mg/dl and 39.5% had an isohemagglutinin titer X1:8. At 12 months post transplant, the following number of children still did not recover immune functions: 1.8% (ALC), 9.5% (CD4), 23.1% (CD4/CD8 ratio), 11.3% (PHA), 5.4% (MLC), 5.7% (IgM), 21.1% (isohemagglutinin titers). Histograms in Figure 1 depict recovery of neutrophils, lymphocytes/ subsets, and T and B-cell function, graphed according to the 3-month interval in which normalization of each parameter was documented.
Infection
A total of 34 patients (59%) developed 39 episodes of infection between the time of neutrophil engraftment and 1 year post transplantation. These infections included 18 episodes of bacteremia, eight episodes of zoster reactivation and one primary varicella infection, five episodes of pneumonia by radiologic or clinical evidence (no organism identified in any of them), two episodes of Clostridium difficile enteritis, two episodes of pharyngitis and one episode each of cellulitis, fungal skin infection, and CMVantigen reactivation. Of 18 patients with bacteremia, eight were caused by Gram-negative organisms and 11 by Grampositive organisms. All patients with bacteremia had indwelling central catheters at the time of infection. Of nine patients with varicella-zoster virus (VZV) infection, six developed infection within 3 months of acyclovir discontinuation.
For the three most common infection types, time to development of infection was 2.471.6 (SD) months for bacterial sepsis, 5.572.6 (SD) months for varicella/zoster infection and 4.673.7 (s.d.) months for pneumonia. Most of the infections (77%) developed by 6 months post transplant. Table 2 lists patients who developed an infection within a year of transplant, their time to infection and time of discontinuation of supportive care measures and IVIG, as surrogate markers of T-and B-cell immunity. Figure 2 depicts mean time to normalization of tests of T-and B-cell functions in patients with and without infection. Although patients with infections took longer to recover all immune functions, except for IgM level, the numbers in this study were too small to confirm that this difference was statistically significant.
Risk factors for infection
Of nine patients who had an infection between 6 and 12 months post transplant, two patients had abnormal in vitro T-cell function at the time of infection and seven developed an infection despite normalization of in vitro T-cell proliferative responses. All patients recovered fully from their infections.
Discussion
Immune reconstitution
Two-thirds of patients developed normal T-cell function (measured by in vitro proliferative assays) by 6 months post transplant, and approximately 90% developed normal Tcell function by 12 months post-transplant. These results are similar to reports in the literature documenting abnormal T-cell function persisting for 6-12 months after autologous transplantation in children and adults. 1, 5, 6, 13 Normal IgM levels developed by 6 months in 75% of our patients, which mirrors earlier reports indicating that normal IgM levels develop 4-6 months after autologus transplant. 1, 5 Of note, neuroblastoma purging of hematopoietic cells did not affect T-or B-cell reconstitution in these patients, despite being associated with delayed neutrophil engraftment.
Infections
Despite our prophylactic measures, infections developed in a large number of children undergoing autologous transplant (59%). Bacteremia and VZV reactivation were the two most common infection types. Bacteremia developed in 31% of patients at a median time of 2.4 months post transplant. A total of 55% of patients with positive blood cultures had a Gram-positive infection and 45% had a Gram-negative infection. This is similar to the published literature, which indicates a predominance of Grampositive infections. [14] [15] [16] [17] [18] [19] [20] The presence of an indwelling central line is the most significant risk factor for Grampositive blood infections. 16, 19 All our patients had indwelling central catheters at the time of diagnosis of blood infection. Although all patients cleared their infection, bacteremias are a life-threatening complication, and the risks and benefits of keeping an indwelling central catheter after discharge from the transplantation unit should be carefully assessed.
Reactivation of varicella-zoster infection occurred in eight patients and one patient developed primary infection. The incidence of VZV infection was 15% in our cohort, similar to the incidence published in the literature, which ranges from 13 to 34%. [21] [22] [23] [24] Six patients developed VZV infection within 3 months of discontinuation of acyclovir prophylaxis (see Table 2 ), and three patients developed VZV while still on prophylactic medications (we do not have information on medication compliance). Development of VZV soon after cessation of antiviral therapy has been Infectious complications after ABMT in children J Machatschek et al previously described. 24 The median time to development of VZV infection was 5.5 months, and in six patients reactivation occurred despite normalization of in vitro T-cell proliferative responses.
Clinically diagnosed pneumonia developed in 8.6% of patients (median time 4.5 months post transplant). None of these patients had documented viral or bacterial pathogens. There were no episodes of Pneumocystis pneumonia in our population. All other documented infections were rare in our cohort and they resolved with standard therapy. There was no correlation between time to recovery of T-or B-cell functions and the risk of infections in this relatively small patient cohort. Most infections (77%) developed by 6 months post-transplant. Even after normalization of in vitro T-cell proliferative responses, patients remained at an increased risk of infection, in particular VZV infection. In vitro T-cell proliferative responses to PHA and MLC did not predict the risk of infections in patients who are more than 6 months post-transplant.
Since the results of this study became available, we have changed our supportive care measures for recipients of autologous transplant, and currently recommend early removal of the indwelling central catheter as well as discontinuation of prophylactic medications including IVIG at 6 months post-transplant.
Conclusions
Most patients recover T-and B-cell immunity by 6 months post transplant. A total of 59% of children undergoing autologous transplant developed an infection between neutrophil engraftment and 1 year post transplant, 77% of which occurred by 6 months post transplant. Early removal of indwelling central venous catheters may decrease the risk of bacterial infections, which are the most common infection type post transplant. Supportive care measures may be discontinued, in most children, by 6-months post transplant, as their risk of infections significantly decreases by that time.
